A Randomized Phase II/III study of the combination of Ce

Project: Research project

Project Details

Description

A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or - refractory ovarian, fallopian tube, or primary peritone
StatusActive
Effective start/end date1/1/1712/31/21

Funding

  • NRG ONCOLOGY FOUNDATION, INC.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.